NASDAQ:APRE

Aprea Therapeutics Q3 2025 Earnings Results & Report

Aprea Therapeutics logo
$0.45 +0.05 (+11.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.46%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.47 versus the -$0.11 consensus estimate, while revenue was $1.85 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Aprea Therapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.11
Beat/Miss
Missed by -$0.36
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aprea Therapeutics Revenue Results

Actual Revenue
$1.85 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Q3 2025 Earnings FAQ

Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.47 per share for Q3 2025, missing the consensus estimate of -$0.11. The report was announced on Wednesday, November 12, 2025.

Aprea Therapeutics reported revenue of $1.85 thousand for Q3 2025.

Aprea Therapeutics Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

View Aprea Therapeutics Profile